Some contraceptive pills may cut ovarian cancer risk: Study


New types of combined — containing both oestrogens and — may reduce the risk of in young women, a study has found.

The study, published by The BMJ, showed that this positive effect strengthened with longer periods of use and persisted for several years after stopping, providing important reassurance for women.


At least 100 million women worldwide are using hormonal every day.

Previous research has shown a reduced risk of in women who take combined oral contraceptives, but most of the evidence relates to the use of older products, containing higher levels of oestrogen and older

Women who use newer and other hormonal also want to know whether they are likely to experience the same benefit.

Researchers at the in Scotland and the in Denmark investigated the influence of newer hormonal contraceptives (combined and progestogen-only products) on overall and specific types of in women of reproductive age.

They analysed data for nearly 1.9 million Danish women aged 15-49 years between 1995 and 2014.

Women were categorised as never users, current or recent users (up to one year after stopping use), or former users (more than one year after stopping use) of different hormonal contraceptives.

Most (86 per cent) of the hormonal contraceptive use related to combined oral products, researchers said.

After taking account of several factors, including age and parity, the researchers found that the number of cases of ovarian cancer were highest in women who had never used hormonal — 7.5 per 100,000 person years).

Among women who had ever used hormonal contraception, the number of cases of ovarian cancer were 3.2 per 100,000 person years.

There was no firm evidence to suggest any protective effect among women who used progestogen-only products, although the researchers point out that few women were exclusive users of these products.

The reduced risk for combined products was seen with nearly all types of ovarian cancer, and there was little evidence of important differences between products containing different types of

Similar results were also found among women followed up to their first switch in contraceptive type.

Based on these figures, researchers said that hormonal prevented an estimated 21 per cent of in this group of women.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)